The Roche Group reported sales of CHF 29.8 billion ($33.7 billion) in the first half, unchanged from a year earlier on a reported basis but up by 5% at constant exchange rates. With product sales reviving and several regulatory approvals in hand, the company plans to increase its dividend in Swiss francs this year. Further details were not provided.
